Roth Capital resumed coverage of CapsoVision (CV) with a Buy rating and $7 price target The firm says the two label expansions in December 2024, to include pediatrics as young as two and remote ingestions, will help to accelerate adoption of the company’s “best-in-class” device. It sees clearance of Gen 1 CapsoCam Colon as well as submissions for CapsoVision’s small bowel artificial intelligence module as additional catalysts for the shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CV: